Direct Healthcare Professional Communication (DHPC) on Xeljanz® (Tofacitinib): increased risk of venous thromboembolic events and increased risk of serious and fatal infections
2020.03.20
Active substance: tofacitinib
Pfizer, in coordination with the European Medicines Agency (EMA) and the Federal Institute for Drugs and Medical Devices (BfArM), informs that a dose-dependent increased risk of serious venous thromboembolic events has been observed in patients treated with tofacitinib.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN